Literature DB >> 831307

Spontaneous thrombosis of an intracranial aneurysm during treatment with epsilon aminocaproic acid.

R M Scott, E Garrido.   

Abstract

The authors report spontaneous thrombosis of a middle cerebral artery aneurysm in a patient receiving the anti-fibrinolytic agent, epsilon aminocaproic acid. Intense vasospasm and profound neurologic deficit accompanied the initial hemorrhage. Follow-up angiography two, four and ten weeks following the initial hemorrhage demonstrated occlusion of the aneurysm and progressive thrombosis of a middle cerebral artery branch despite the disappearance of vasospasm. The patient had a persistent hemiparesis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 831307

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  5 in total

Review 1.  Aneurysm regression after coil embolization of a concurrent aneurysm.

Authors:  Michael M Chow; William E Thorell; Peter A Rasmussen
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

2.  The changing angiographic appearance of an arteriovenous malformation after subarachnoid hemorrhage.

Authors:  D London; D Enzmann
Journal:  Neuroradiology       Date:  1981       Impact factor: 2.804

Review 3.  Thromboembolic complication induced stable occlusion of a ruptured basilar tip aneurysm. Case report and review of the literature.

Authors:  Z Kulcsár; Z Berentei; M Marosföi; J Vajda; I Szikora
Journal:  Interv Neuroradiol       Date:  2010-03-25       Impact factor: 1.610

Review 4.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.

Authors:  H Fodstad; B Liliequist
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.